NASDAQ
29.09USD
+1.55 (+5.65%)
We have scored 10 news catalysts on Mineralys Therapeutics, Inc. (MLYS) over the past 12 months. The biggest single-day move next to one of them came Nov 10, 2025, when MLYS closed +17.0%: “Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update”. Coverage across the window leans positive (average ticker sentiment +0.41). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.6B
P/E
—
EPS
—
Beta
0.68
52W range
22.3-47.65
Day range
28.03–29.52
Open
28.12
Prev close
27.54
Volume
258.5K
Avg volume
1.3M
Dividend
0.00
IPO
2023-02-10
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Mineralys Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MLYS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
